A retrospective analysis from Israel suggested that markers of poor hydration are linked to increased risks of hypertension ...

Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues.

Milestone Pharmaceuticals MIST recently announced that the FDA has issued a Complete Response Letter (“CRL”) for its New Drug Application (“NDA”) seeking approval for CARDAMYST (etripamil ...

H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...

In other recent news, Milestone Pharmaceuticals has encountered a setback with its New Drug Application for CARDAMYST™ (etripamil) nasal spray after receiving a Complete Response Letter from the FDA.

The facility changed ownership during the review of the NDA. “We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help ...

Joe Oliveto, President and CEO of Milestone Pharmaceuticals, expressed disappointment over the CRL but reaffirmed the company’s commitment to CARDAMYST as a potential novel treatment for paroxysmal ...

Cardiology drug and device makers will be back in the spotlight this weekend as the annual scientific meeting of the American College of Cardiology gets underway in Chicago.